跳至主要内容
临床试验/EUCTR2006-002605-31-AT
EUCTR2006-002605-31-AT进行中(未招募)不适用

ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILUREA double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure - Aldo-DHF

Georg-August-Universität Göttingen0 个研究点目标入组 420 人开始时间: 2008年8月27日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
420

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • · Current heart failure symptoms consistent with NYHA II or beyond
  • · Left ventricular ejection fraction (LVEF) = 50% at rest
  • · Sinus rhythm or atrial fibrillation
  • · if sinus rhythm Echocardiographic parameters of diastolic dysfunction (Grade = I, see Appendix)
  • · Peak VO2 = 25 ml/kg/min
  • · Males and females of age = 50 years
  • · Written informed consent of the patient
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients will be excluded for ANY ONE of the following reasons:
  • · definite or probable pulmonary disease (VC<80% or FEV1<80% of reference values on spirometry)
  • · severe obesity (BMI = 36 kg/m2)
  • · psychological disorders with suspected interaction to study outcome
  • · Prior documented intolerance to an aldosterone receptor antagonist
  • · Prior documented systolic heart failure (LVEF = 40%)
  • · Changes in concomitant medication within the last two weeks prior screening visit
  • · Significant coronary artery disease (current angina pectoris or ischemia on stress tests; untreated coronary stenosis >50%; Myocardial infarction or CABAG within the last 3 months)
  • · Known contraindications for spironolactone
  • · Significant laboratory abnormalities (potassium = 5.1 mmol/L; hemoglobin = 11g/dL, hematocrit = 33%)
  • · Significant renal dysfunction (creatinine > 1.8 mg/dL or eGFR < 30 mL/min/1,73m²)
  • · Concomitant therapy with a potassium-sparing diuretic (e.g., triamterene, amiloride), potassium substitution, or high-dose acetylsalicylic acid (>500 mg/d) or permanent intake of non-steroidal antiphlogistic agents
  • · Insulin-dependent diabetes mellitus with a history of ketoacidosis
  • · Significant hypotension (blood pressure < 90 mmHg systolic and/or 50 mmHg diastolic)
  • · Pregnant or nursing women
  • · Women with child bearing potency without effective contraception (i.e. implants, injectables, combined oral contraceptives, some IUDs or vasectomised partner)

研究者

相似试验

进行中(未招募)
不适用
ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILUREA double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure - Aldo-DHFDiastolic Heart Failure
EUCTR2006-002605-31-DEGeorg-August-Universität Göttingen
已完成
2 期
Aldosterone receptor blockade in Diastolic Heart Failure: a double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failureDiastolic heart failureHeart failureCirculatory System
ISRCTN94726526Georg-August University of Göttingen (Georg-August-Universität Göttingen) (Germany)422
进行中(未招募)
1 期
ALdosterone antagonist Chronic HEModialysis Interventional Survival Trialend-stage renal failure (ESRF)cardiovascular complicationMedDRA version: 20.0Level: PTClassification code 10007649Term: Cardiovascular disorderSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10050441Term: Chronic renal insufficiencySystem Organ Class: 100000004857
EUCTR2012-002856-18-BECHRU de Brest825
进行中(未招募)
不适用
ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial
EUCTR2012-002856-18-FRCHRU de Brest
进行中(未招募)
1 期
Effects of Spironolactone in Heart Failure with Preserved Ejection Fraction: Measured by CMR, Echo, Excercise Capacity and Quality of Life Questionaire
EUCTR2013-000867-10-GBniversity of Leeds51